Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
复制标题
DOI：
10.1002/ijc.25007
复制
发表时间：
2010-07-01
影响因子：
6.4
通讯作者：
Du, Xiang
中科院分区：
文献类型：
--
作者：
Huang, Zhaohui;Huang, Dan;Du, Xiang
MicroRNA(MiRNA)为癌症的分子诊断开辟了新的领域。然而，血浆/血清中循环miRNAs在癌症诊断中的作用尚不清楚。本研究旨在探讨血浆miRNAs能否作为结直肠癌(CRC)早期检测的生物标志物。采用实时荧光定量RT-PCR方法检测了12种miRNAs(miR-134、146a、-17-3p、-181d、-191、-221、-222、-223、-25、-29a、-320a和-92a)在进展期大肠肿瘤(癌和腺瘤)患者和正常对照血浆中的表达水平。我们发现血浆miR-29a和miR-92a对晚期肿瘤有显著的诊断价值。MIR-29a的AUC(ROC曲线下面积)为0.844，MIR-92a的AUC值为0.838。更重要的是，这两个miRNA还可以区分晚期腺瘤和对照组，miR-29a和miR-92a的AUC值分别为0.769和0.749。联合应用这两种miRNAs进行ROC分析，AUC值为0.883，鉴别结直肠癌的灵敏度为83.0%，特异度为84.7%；AUC值为0.773，鉴别晚期腺瘤的灵敏度为73.0%，特异度为79.7%。综上所述，这些数据表明，血浆miR-29a和miR-92a作为一种新的非侵入性生物标志物在早期检测结直肠癌方面具有很强的潜力。
MicroRNA (miRNA) opens up a new field for molecular diagnosis of cancer. However, the role of circulating miRNAs in plasma/ serum in cancer diagnosis is not clear. The aim of this study was to investigate whether plasma miRNAs can be used as biomarkers for the early detection of colorectal carcinoma (CRC). We measured the levels of 12 miRNAs (miR-134, 146a, -17-3p, -181d, -191, -221, -222, -223, -25, -29a, -320a and -92a) in plasma samples from patients with advanced colorectal neoplasia (carcinomas and advanced adenomas) and healthy controls using real-time RT-PCR. We found that plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia. MiR-29a yielded an AUC (the areas under the ROC curve) of 0.844 and miR-92a yielded an AUC of 0.838 in discriminating CRC from controls. More importantly, these 2 miRNAs also could discriminate advanced adenomas from controls and yielded an AUC of 0.769 for miR-29a and 0.749 for miR-92a. Combined ROC analyses using these 2 miRNAs revealed an elevated AUC of 0.883 with 83.0% sensitivity and 84.7% specificity in discriminating CRC, and AUC of 0.773 with 73.0% sensitivity and 79.7% specificity in discriminating advanced adenomas. Collectively, these data suggest that plasma miR-29a and miR-92a have strong potential as novel noninvasive biomarkers for early detection of CRC.